Amol Akhade/LinkedIn
Jan 26, 2025, 07:35
Amol Akhade: Additon of trastuzumab With or without Pertuzumab in her2 postive stomach cancer
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, posted on X:
“Innovation trial. Can additon of trastuzumab With or without Pertuzumab into perioperative chemo makes a difference in OS for her2 postive stomach cancer. Answer is NO. Negative trial. May be her2 is not a strong driver pathway in stomach as it is in breast.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 6, 2025, 13:51
Mar 6, 2025, 12:54
Mar 6, 2025, 12:37
Mar 6, 2025, 12:21
Mar 6, 2025, 10:44
Mar 6, 2025, 10:40
Mar 6, 2025, 10:30